DNA Damage Response Proteins and Cervical Cancer Treatment
Author Information
Author(s): Catharina Beskow, Lena Kanter, Åsa Holgersson, Björn Nilsson, Bo Frankendal, Eva Åvall-Lundqvist, Rolf Lewensohn
Primary Institution: Karolinska University Hospital
Hypothesis
Low percentage immunostaining of DNA-PKcs in primary tumour would result in pCR after RT to a greater extent than high immunopositivity of DNA-PKcs.
Conclusion
The study found that immunohistochemical assessment of DNA-PK complex cannot be used as a predictive marker for clinical response to brachytherapy in early stages of cervical carcinoma.
Supporting Evidence
- 85 patients demonstrated pathologic complete remission after radiotherapy.
- Expression of DNA-PKcs positively correlated with Ku86 and Ku70.
- Positive p53 tumours were significantly more common among non-pCR cases.
Takeaway
Researchers looked at proteins in cervical cancer to see if they could predict how well patients would respond to radiation treatment, but they found no clear link.
Methodology
Formalin-fixed primary tumour biopsies were analyzed by immunohistochemistry to assess protein expression and correlate it with treatment response.
Potential Biases
Potential bias in patient selection and treatment response evaluation.
Limitations
The study only included early-stage cervical cancer patients, which may limit the generalizability of the findings.
Participant Demographics
Patients aged 23 to 75 years, mean age 44 years, with FIGO stage IB–IIA cervical cancer.
Statistical Information
P-Value
0.031
Statistical Significance
p=0.031
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website